Yao Dan, Jiang Jiefeng, Zhou Qianyun, Feng Caiyun, Chu Jianping, Chen Zhiyan, Yang Jie, Xia Jinying, Chen Yujia
Department of Endocrinology, Xiangshan Hospital of TCM Medical and Health Group, Xiangshan, Ningbo, People's Republic of China.
Department of Endocrinology, Ningbo First Hospital, Ningbo, People's Republic of China.
Diabetes Metab Syndr Obes. 2024 Sep 16;17:3463-3475. doi: 10.2147/DMSO.S456466. eCollection 2024.
In recent years, there have been hundreds of reports on insulin autoimmune syndrome (IAS) globally; however, fewer than a hundred patients have undergone genetic testing. Our objective is to examine the background of IAS and the variations in drugs that trigger it among patients who have been genetically tested, aiming to deepen our understanding of this condition. HLA Analysis of 68 cases showed that DR4 is predominant, especially in individuals of East Asian descent, notably in DRB1 *0406. Methimazole was the primary drug associated with IAS in these populations, while in Caucasian individuals, the emphasis was on DRB1 *0403, with lipoic acid being the common inducer. The key factor determining disease risk is the combination of chromosomal allele variations, with HLA class II allele DR4 positive patients showing a strong association with DQA1 *0301/DQB1 *0302.
近年来,全球已有数百篇关于胰岛素自身免疫综合征(IAS)的报告;然而,接受基因检测的患者不到一百例。我们的目的是研究IAS的背景以及在接受基因检测的患者中引发该综合征的药物差异,旨在加深我们对这种疾病的理解。对68例病例的HLA分析表明,DR4占主导地位,尤其是在东亚血统的个体中,特别是在DRB10406中。甲巯咪唑是这些人群中与IAS相关的主要药物,而在白种人个体中,重点是DRB10403,硫辛酸是常见的诱发因素。决定疾病风险的关键因素是染色体等位基因变异的组合,HLA II类等位基因DR4阳性患者与DQA10301/DQB10302密切相关。